Novi Systems Ltd
Menu
  • Introducing New Automated Nasal Spray Innovation

    Introducing New Automated Nasal Spray Innovation

Introducing new Automated Nasal Spray Testing System

Nasal drug delivery devices have been in use for more than 40 years. Historically they were widely recognised as a method of drug delivery for allergic and non-allergic rhinitis and nasal congestion. Fast forward to today and the nasal spray is now used to treat other issues that require medication to enter the bloodstream or immune system quickly.

Evidence suggests that medications to treat diseases such as Parkinson’s and Alzheimer’s and even flu vaccinations can be delivered effectively via nasal sprays; it’s no wonder that the market for nasal delivery devices is rapidly increasing. Predictions state that by 2030 there will be over 1 billion people over the age of 65 worldwide*.

Novi has developed a nasal spray module in collaboration with our customers that, when attached to the Vertus Shake and Fire system for pMDIs, negates labs from requiring additional pieces of equipment. Saving valuable workspace whilst optimising the analyst’s time. When fitted with the nasal spray adaptor, the Vertus provides the following functionality:

  • Full control over the firing forces
  • Measure the distance of travel of the spray during firing
  • Control when the pauses in testing should take place ie. between sprays
  • Calculate shot weights
  • The ability to shake the nasal spray (if required)
  • Manage the strength of the air flow to ensure consistency of testing
  • Remove any waste product from the nozzle during testing

A critical factor in testing is to ensure that the nasal spray meets the claim stated on the packaging ie. ‘label claim’. One of the ways this can be verified is by weighing the spray before testing and after the test has been completed.

The nasal spray system has been developed to fully conform with FDA and EMA regulations.

To find out more, why not visit our stand at DDL 2018, stand 240.

 

*Source: https://www.europeanpharmaceuticalreview.com/article/3258/who-nose/